Physiology of Lipid Droplets and Triglyceride Storage
脂滴和甘油三酯储存的生理学
基本信息
- 批准号:8888803
- 负责人:
- 金额:$ 56.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-05-01 至 2019-04-30
- 项目状态:已结题
- 来源:
- 关键词:CaliberCellsCirrhosisComorbidityCultured CellsDevelopmentDiabetes MellitusDiseaseDisease PathwayDisease ProgressionDrug Metabolic DetoxicationDrug TargetingEnzymesEvolutionFatty AcidsFatty LiverFatty acid glycerol estersGenetic ModelsHeart DiseasesHepaticHepatocyteHypertriglyceridemiaIndividualInsulin ResistanceLabelLightLinkLipidsLiverLiver diseasesMediatingMetabolic DiseasesMetabolic PathwayMetabolismModelingMorbidity - disease rateMusNon-Insulin-Dependent Diabetes MellitusObesityObesity associated diseasePathway interactionsPharmacologic SubstancePhysiologic pulsePhysiologicalPhysiologyPopulationProcessProtein IsoformsPublic HealthRelative (related person)ResearchSourceStable Isotope LabelingSteatohepatitisStudy modelsSurfaceSystemTestingTissuesTriglyceride MetabolismTriglyceridesVery low density lipoproteinWild Type Mousecell typediabeticflyinsightlipid biosynthesislipid metabolismmortalitynon-alcoholic fatty liveroverexpressionpandemic diseasepreventpublic health relevanceresearch study
项目摘要
DESCRIPTION (provided by applicant): Diseases of metabolic excess constitute the most prominent "killers" in the developed world. At the heart of these diseases lies excessive storage of triacylglycerols (triglycerides, TG), which gives rise to obesity, lipotoxicity, and associated o-morbidities, such as non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). TGs are stored in cytosolic lipid droplets (LDs). Our research recently revealed two distinct classes o LDs: smaller LDs (sLD) and larger and more heterogeneous expanding LDs (eLDs). LDs of the latter class grow by local TG synthesis on the LD surface, mediated by isoforms of TG synthesis enzymes, such as GPAT4 and DGAT2. We discovered that these different LD populations are present in nearly all types of cells. However, their relative contributions to TG storage and secretion in tissues are unknown, as are their functions in physiology and metabolism. Here we propose experiments in murine hepatocytes and liver that will elucidate the functions of eLDs and sLDs in hepatic TG metabolism. We hypothesize that eLDs, conserved throughout evolution, represent the first tier of TG storage: eLD formation allows LDs to expand to a large size, accommodating the majority of synthesized TG in cells and segregating lipids from other lipid metabolic pathways and ER functions. When the capacity of eLDs for TG storage is overwhelmed, sLDs form and provide a second line of defense by esterifying these molecules. To test this model for the function of different LD classes, we will determine the physiological function of eLDs and sLDs by determining a) the relative contributions of the eLD and sLD pathways to LD formation and TG storage in hepatocytes, b) the requirements of the eLD and sLD pathways for TG secretion (as components of very low-density lipoproteins, or VLDL) in the liver, and c) the relative contributions of the eLD and sLD pathways to the development of NAFLD and NASH in the liver. Our results will provide the first insights of how different LD classes function to store or secrete TG. Moreover, they will shed light on which of these different
LD classes are important for preventing the development of NASH in the setting of NAFLD. Insights from these studies should provide new information for pharmaceutical targeting of drugs to treat diseases of TG excess, such as hepatic steatosis and VLDL-related hypertriglyceridemia.
描述(由申请人提供):代谢过度疾病是发达国家最突出的“杀手”。这些疾病的核心是三酰甘油(甘油三酯,TG)的过度储存,导致肥胖、脂肪毒性和相关的o-发病率,如非酒精性脂肪性肝病(NAFLD)和脂肪性肝炎(NASH)。tg储存在细胞质脂滴(ld)中。我们的研究最近揭示了两种不同类型的ld:较小的ld (sLD)和较大且更异构的扩展ld (eld)。后一类的LD是由TG合成酶的异构体GPAT4和DGAT2介导,通过LD表面的局部TG合成来生长的。我们发现这些不同的LD群体存在于几乎所有类型的细胞中。然而,它们在组织中对TG储存和分泌的相对贡献是未知的,它们在生理和代谢中的功能也是未知的。在此,我们提出在小鼠肝细胞和肝脏中进行实验,以阐明eld和sLDs在肝脏TG代谢中的功能。我们假设,在整个进化过程中保守的eLD代表了TG储存的第一层:eLD的形成允许ld扩展到大尺寸,容纳细胞中大部分合成的TG,并从其他脂质代谢途径和内质网功能中分离脂质。当用于TG存储的eld的容量被淹没时,通过将这些分子酯化形成sld并提供第二道防线。为了测试这个模型不同的LD类的函数,我们将决定古人的生理功能和sLD确定)的相对贡献古人和sLD LD和TG存储路径在肝细胞,b)的要求古人和TG sLD途径分泌(作为组件的低密度脂蛋白,或VLDL)在肝脏,和c)的相对贡献古人和sLD通路的发展非酒精性脂肪肝和纳什在肝脏。我们的研究结果将首次揭示不同的LD类如何储存或分泌TG。此外,它们将揭示这些不同的
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT V FARESE其他文献
ROBERT V FARESE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT V FARESE', 18)}}的其他基金
Lipotoxic Protective Response of the Endoplasmic Reticulum
内质网的脂毒性保护反应
- 批准号:
10176932 - 财政年份:2021
- 资助金额:
$ 56.73万 - 项目类别:
Lipotoxic Protective Response of the Endoplasmic Reticulum
内质网的脂毒性保护反应
- 批准号:
10376867 - 财政年份:2021
- 资助金额:
$ 56.73万 - 项目类别:
Lipotoxic Protective Response of the Endoplasmic Reticulum
内质网的脂毒性保护反应
- 批准号:
10706013 - 财政年份:2021
- 资助金额:
$ 56.73万 - 项目类别:
Lipotoxic Protective Response of the Endoplasmic Reticulum
内质网的脂毒性保护反应
- 批准号:
10551904 - 财政年份:2021
- 资助金额:
$ 56.73万 - 项目类别:
Lipid Droplets and Transcriptional Regulation of Metabolism
脂滴和代谢的转录调控
- 批准号:
10696383 - 财政年份:2020
- 资助金额:
$ 56.73万 - 项目类别:
Lipid Droplets and Transcriptional Regulation of Metabolism
脂滴和代谢的转录调控
- 批准号:
10356853 - 财政年份:2020
- 资助金额:
$ 56.73万 - 项目类别:
相似国自然基金
分化肌细胞脱细胞ECM-cells sheet 3D
支架构建及其促进容积性肌组织缺损再
生修复应用及机制研究
- 批准号:
- 批准年份:2025
- 资助金额:10.0 万元
- 项目类别:省市级项目
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
- 批准号:
- 批准年份:2020
- 资助金额:56 万元
- 项目类别:面上项目
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
- 批准号:82070825
- 批准年份:2020
- 资助金额:53 万元
- 项目类别:面上项目
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
- 批准号:81903002
- 批准年份:2019
- 资助金额:20.5 万元
- 项目类别:青年科学基金项目
HA/CD44在乳腺癌转移“先导细胞”(leader cells)侵袭中的作用及机制研究
- 批准号:81402419
- 批准年份:2014
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
双模式编码的慢病毒载体转染C6 Glioma Cells的影像学研究
- 批准号:81271563
- 批准年份:2012
- 资助金额:60.0 万元
- 项目类别:面上项目
树突状细胞(Dendritic cells,DCs)介导的黏膜免疫对猪轮状病毒(PRV)感染的分子作用机制研究
- 批准号:31272541
- 批准年份:2012
- 资助金额:82.0 万元
- 项目类别:面上项目
MTA2在睾丸支持细胞(Sertoli cells)中的功能和机制研究
- 批准号:31271248
- 批准年份:2012
- 资助金额:80.0 万元
- 项目类别:面上项目
无外源性基因iPS cells向肠细胞分化及对肠损伤的修复
- 批准号:81160050
- 批准年份:2011
- 资助金额:49.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Elucidation of the role of hematopoietic cells in the development and progression of liver cirrhosis due to NASH and establishment of new therapeutic targets.
阐明造血细胞在NASH引起的肝硬化发生和进展中的作用并建立新的治疗靶点。
- 批准号:
19K17404 - 财政年份:2019
- 资助金额:
$ 56.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of the core technologies of regenerative therapy with human somatic stem cells for cirrhosis and liver failure
开发人体干细胞再生治疗肝硬化、肝衰竭的核心技术
- 批准号:
18H02866 - 财政年份:2018
- 资助金额:
$ 56.73万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
A pilot study to evaluate the safety of intravenously administered human amnion epithelial cells in patients with compensated cirrhosis
一项评估代偿性肝硬化患者静脉注射人羊膜上皮细胞安全性的初步研究
- 批准号:
nhmrc : GNT1124020 - 财政年份:2017
- 资助金额:
$ 56.73万 - 项目类别:
Project Grants
A pilot study to evaluate the safety of intravenously administered human amnion epithelial cells in patients with compensated cirrhosis
一项评估代偿性肝硬化患者静脉注射人羊膜上皮细胞安全性的初步研究
- 批准号:
nhmrc : 1124020 - 财政年份:2017
- 资助金额:
$ 56.73万 - 项目类别:
Project Grants
Development of new therapy for liver cirrhosis using human iPS cells
利用人类 iPS 细胞开发肝硬化新疗法
- 批准号:
16K15596 - 财政年份:2016
- 资助金额:
$ 56.73万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Development of a new treatment for liver cirrhosis with the innovative drug nanocarrier targeting hepatic stellate cells
靶向肝星状细胞的创新药物纳米载体开发肝硬化新疗法
- 批准号:
15K15499 - 财政年份:2015
- 资助金额:
$ 56.73万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Basic studies into development of novel preventive and regenerative therapy for hepatocarcinogenic cirrhosis using bone marrow-derived cells having redox-regulatory capacity
利用具有氧化还原调节能力的骨髓来源细胞开发新型肝癌性肝硬化预防和再生疗法的基础研究
- 批准号:
24790703 - 财政年份:2012
- 资助金额:
$ 56.73万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Significance of estrogen on biliary epithelial cells in the pathogenesis of primary biliary cirrhosis
雌激素对胆道上皮细胞的影响在原发性胆汁性肝硬化发病机制中的意义
- 批准号:
23590393 - 财政年份:2011
- 资助金额:
$ 56.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The treatment of liver cirrhosis by transplantation of the hepatic progenitor cells with transformation
转化肝祖细胞移植治疗肝硬化
- 批准号:
23591987 - 财政年份:2011
- 资助金额:
$ 56.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of regulatory B cells in a murine model of primary biliary cirrhosis and fundamental examination for clinical application
原发性胆汁性肝硬化小鼠模型中调节性B细胞的鉴定及临床应用基础检查
- 批准号:
22890024 - 财政年份:2010
- 资助金额:
$ 56.73万 - 项目类别:
Grant-in-Aid for Research Activity Start-up